Cargando…
Overexpression of miR-15b Promotes Resistance to Sunitinib in Renal Cell Carcinoma
Aim: Sunitinib remains the frontline treatment for metastatic clear-cell renal cell carcinoma (ccRCC). Drug resistance is inevitable and related mechanism warrant insightful elaboration. Methods: In silico data mining of GEO and TCGA datasets was performed to identify potential target micro-RNA. In...
Autores principales: | Lu, Lu, Li, Yanmin, Wen, Hui, Feng, Chenchen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6603409/ https://www.ncbi.nlm.nih.gov/pubmed/31293642 http://dx.doi.org/10.7150/jca.31676 |
Ejemplares similares
-
PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance
por: Feng, Chenchen, et al.
Publicado: (2021) -
Correction to: PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance
por: Feng, Chenchen, et al.
Publicado: (2021) -
miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib
por: Merhautova, Jana, et al.
Publicado: (2015) -
miR-96-5p targets PTEN to mediate sunitinib resistance in clear cell renal cell carcinoma
por: Park, Sang Eun, et al.
Publicado: (2022) -
Sunitinib resistance in renal cell carcinoma
por: Morais, Christudas
Publicado: (2014)